Brazil's list of 'retaliation' products against USA to include medicines for the first time

17 February 2010

As a result of last year's World Trade Organization upholding of Brazilian complaints against the USA on subsidies granted to cotton producer, the Brazilian government has taken a serious step forward to apply trade barriers against American products in the amount of $560 million and to further impose $270 million retaliatory sanctions on services and intellectual property rights.

Firstly, on February 9 the CAMEX (Camara do Comercio Exterior - the Brazilian Board Trade) approved an updated list of 220 American products that will suffer a tariff increase of up 100% of their value when imported into Brazil.

A day later, Brazil's President, Luiz Lula da Silva, signed a provisional measure or interim measure 482 of February 10, 2010 (full text in Portuguese is available at https://www.planalto.gov.br/ccivil_03/_Ato2007-2010/2010/Mpv/482.htm ) allowing the suspension and limitation of Intellectual Property rights of citizens or companies domiciled in countries that violate the WTO's trade rules, explains a blogger on the IP Tango site.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical